Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million , at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® revenue of $13.6 million , at the upper end of the range provided in January Ended[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]

BURLINGTON, Mass. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Company anticipates Q4 2023 net FUROSCIX   revenue to be approximately $5.9 to $6.1 million ; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4 Inventory levels at the end of Q4 2023 consistent[…]